S.I.I.T. has a long history of innovation. Innovation is the hearth of our company and is the key to S.I.I.T.’s success. It depends on creative inventors group , who propose technologies, product concepts, solutions and benefit that address on consumer needs.
Patenting is a mean to protect our innovation and to sustain and expand S.I.I.T. competitive advantage. To this aim the Research & Development group make an important contribution to S.I.I.T.’s patent portfolio each year, and supports S.I.I.T.’s product portfolio advancing S.I.I.T.’s leadership in Health solutions.
Formulation Patents
EP3067042 (A1)
Floating system for the treatment of gastric disorders
New two-layer mucoadhesive floating tablet to obtain controlled gastric release for the treatment of gastric disorders
CY1119636 (T1)
Medicinal preparation based on diosmectite
An innovative Ready-to-use oral suspension containing micronized particles of diosmectite and karaya gum for the treatment of diarrhoea
EP2942050 (A1)
A sprayable oily composition based on liposoluble vitamins of the group D and use thereof
An innovative oil-based spray to deliver vitamin D for the treatment of disorders associated to vitamin deficiencies.
EP3357492 (A1)
Multilayer tablet for administration of magnesium
An original multilayer tablet for a time and site-controlled release of magnesium, used to treat magnesium deficiency
MI2011A000332
Formulations with melatonin with pulsatil or sequential release and preparation method
Composition with multilayers tablet for time-controlled release of melatonin, a rapid layer release in 5 minutes and a slow layer within 4 hours after the intake
102011901921888
Inclusion complex based on cyclodextrin and vegetable oil and its use
New composition based on cyclodextrin and vegetable oil
Finished Products Patents
EP2942063 (A1)
Composition for fluidizing mucus comprising chitosan and copolymers
An innovative nasal spray containing chitosan from vegetable source for oral or topical use for treatment of common cold, flu, nasal infections, rhinitis, allergic rhinitis.
EP3184115 (A1)
Oral compositions for the treatment of gastroesophageal reflux disease
An innovative product based on the association of tamarind extract, alginic acid and salt- carbonate and/or hydrogen carbonate for the treatment of gastroesophageal reflux disease and pyrosis
EP3225239 (A1)
Body weight control preparation based on chitosan and cellulose
New formulation based on polysaccharides able to capture fats. The synergism action of vegetal chitosan, able to bind fatty acids, and powdered cellulose, able to jellified, ensures efficacy in the control of obesity, weight and cholesterol and triglycerides
EP1923067 (A1)
Compositions containing phaseolus vulgaris extract and alpinia officinarum extract for the prevention and treatment of obesity and type II diabetes
New compositions based on Phaseolus vulgaris extract and Alpinia officinarum extract for the prevention and treatment of obesity and type II diabetes
US2006257332 (A1)
Anticaries compositions containing phaseolamin
Innovative compositions based on salivar ptyalin inhibitors with anti-inflammatory, soothing, abrasive, antibacterial action
SI1911455 (T1)
Topical vaginal pharmaceutical compositions
Innovative topical vaginal formulation based on lactobacilli, lactic acid and extract of garlic for vaginal infections
EP2014181 (A2)
Compositions based on prebiotic and immunogenic ingredients for the prevention and treatment of gastroenteric disorders caused by dysbiosis and/ or alterations of the normal intestinal flora
New compositions containing bifidogenic and lactogenic prebiotic ingredients and immunogenic ingredients able to promote the proliferation and colonisation of bifidobacteria and lactic acid bacteria in the intestine, for the prevention and treatment of gastroenteric disorders.
EP2018868 (A1)
Compositions for the treatment and prevention of vertigo and tinnitus including citicoline, ginkgo biloba extract and dimeric flavones of ginkgo biloba
Innovative formulation containing: citicoline, Ginkgo biloba extract; and dimeric flavones of Ginkgo biloba; for the treatment and prevention of vertigo and tinnitus.
US2005186278 (A1)
Gastroprotected formulations containing alph-amylase inhibitors
Gastroresistant formulations with enteric coating based on phaseolamin, an inhibitor of alpha-amylase
MI2014A001683
Oral formulations with buckthorn extract
Innovative formulation with buckthorn extract for the wellness of immunitary system
MI2004A000289
Antiematic composition based on vegetal extract and vitamin b6
New composition based on vegetal extract and vitamin B6 with antiemetic properties
